Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study-Reference-Cited by-同舟云学术

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

Published:2017-02 Issue:2 Volume:18 Page:230-240
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Seymour John F,Ma Shuo,Brander Danielle M,Choi Michael Y,Barrientos Jacqueline,Davids Matthew S,Anderson Mary Ann,Beaven Anne W,Rosen Steven T,Tam Constantine S,Prine Betty,Agarwal Suresh K,Munasinghe Wijith,Zhu Ming,Lash L Leanne,Desai Monali,Cerri Elisa,Verdugo Maria,Kim Su Young,Humerickhouse Rod A,Gordon Gary B,Kipps Thomas J,Roberts Andrew W

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. The Bcl-2 apoptotic switch in cancer development and therapy;Adams;Oncogene,2007

2. The BCL-2 protein family: opposing activities that mediate cell death;Youle;Nat Rev Mol Cell Biol,2008

3. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia;Roberts;N Engl J Med,2016

4. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease;Roberts;J Clin Oncol,2012

5. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study;Stilgenbauer;Lancet Oncol,2016

Cited by 286 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia;Leukemia & Lymphoma;2024-09-02

2. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions;Blood;2024-08-22

3. Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies;Discover Oncology;2024-07-26

4. BCL-2 inhibition in haematological malignancies: Clinical application and complications;Blood Reviews;2024-05

5. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor;Clinical and Translational Science;2024-05